JPMorgan on MicroPort Medical (0853.HK): Lease Uncertainty, Suspension and Delayed 1H26 Results May Weigh on Sentiment
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
JPMorgan reiterates Overweight on MicroPort Medical (0853.HK) with a December 2026 target price of HK$18.00, against HK$6.07 at the August 31 close, while flagging that lease uncertainty, trading suspension and delayed interim results could hit sentiment. The company voluntarily disclosed unresolved renewal talks for most of its Shanghai property and suspended trading from September 1, 2026 pending 1H26 results; recoverability of a RMB295.99 million deposit held with the landlord is still being assessed. The original five-year lease covering 126,370 sqm of custom-built facilities expired on July 31, 2026; only three subsidiaries (13,872.64 sqm combined) have signed new leases through July 31, 2031, with MicroPort CardioFlow committing RMB137.28 million of total rent for two premises of 13,677.04 sqm. Eight subsidiaries spanning 74,686.84 sqm are still negotiating rent, term and deposit terms. Two open questions stand out: whether the deposit is refunded, offset against rent or impaired; and related-party dynamics, since landlord BlueOrange Capital is an indirect subsidiary of Real & Realistic Foundation, a declared charity invested in MicroPort subsidiaries and holding under 2.2% of CardioFlow. H-share units including Medbot (2252 HK, Overweight) are suspended; its IR confirms unchanged operations and operating finances, though no resumption timeline exists. Watch interim results, deposit clarity, final lease terms and auditor commentary.